Bernstein raised the firm’s price target on BeiGene (ONC) to $259 from $207 and keeps a Market Perform rating on the shares. The firm sees more ...

Bernstein analyst Rebecca Liang maintained a Hold rating on BeiGene (ONC – Research Report) today and set a price target of $259.00. The ...

Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.

Giancarlo Benelli brings over two decades of experience in the pharmaceutical industry, rooted in his unique journey from ...

Baker Brothers' 13F portfolio value decreased from $9.65B to $9.36B. Check out the portfolio's top holdings and notable stake ...

Ken Kato, MD, PhD, and Harry H. Yoon, MD, MHS, discussed the recent FDA approval of tislelizumab in the first line for patients with esophageal squamous cell carcinoma.

China’s obesity crisis is a sizeable profit opportunity. More than half of Chinese adults are overweight or obese — a figure expected to hit two-thirds by 2030. That is nearly 900mn people, a market ...

Burning Rock Biotech Limited’s BNR share price has dipped by 13.43%, which has investors questioning if this is right time to buy.

Amgen and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an investigational T-cell ...

Beijing-based pharma, BeiGene’s Brukinsa (zanubrutinib) has been approved by the US Food and Drug Administration (FDA) for chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL).

After hours: March 7 at 7:54:21 PM EST Loading Chart for ONC ...